For instance, combining ROS-inducing agents with PD-1 or PD-L1 inhibitors has shown promise in preclinical models, as the increased oxidative stress in resistant cancer cells can sensitize them to immune-mediated cell death [115]. Here, CD274 is linked to cancer.